Probably most, of the work lies in developing computer models and software to extract relevance from the mass of data produced from the testing.

It will be necessary to extract and identify complex patterns embedded in the data via data mining. All these advances will lead to the rapid development, of new diagnostic methods and therapeutic products using genomic information and, hopefully, to the improvement of patient care. Although pharmacogenetics is aimed at improving patient care rather than acquiring knowledge about, disease genes, the latter may well be a spin-off of the former. The initial impetus for pharmacogenetics came from the search for disease genes and Inhibitors,research,lifescience,medical the establishment of molecular genetic diagnosis; however, in the future the opposite can be expected. The subdivision of the population into responders

and nonresponders to a particular drug may provide an invaluable starting point for the association of genetic variation with particular phenotypes. When performed in an ethical way with a Inhibitors,research,lifescience,medical laudable and healthy aim, pharmacogenetics and the effective testing for drug response can provide hope for a future of genetic testing in the best, interests of patients and their relatives. Selected abbreviations and acronyms ADR adverse drug reaction AD Alzheimer’s disease bp base pair CYP cytochrome P450 LD linkage disequilibrium PM poor metabolizer SNP single Inhibitors,research,lifescience,medical Inhibitors,research,lifescience,medical nucleotide polymorphism
Depressive disorders are a leading cause of disability worldwide.1,2 By the year 2020, unipolar major depression is projected to be the second leading cause of disability-adjusted life years (DALYS) all over the world.1

Depressive disorders greatly impact morbidity, health care utilization, and medical costs. Despite advances in psych opharmacology and the reported high rates of treatment success (usually between 50% and 70%), the general rule of thumb is that less than half of patients beginning a Inhibitors,research,lifescience,medical course of antidepressant treatment will reach remission with that treatment.3 This implies that a significant proportion of depressed patients either do not respond or continue to have residual symptoms despite treatment with antidepressants. Major depression that does not resolve with adequate antidepressant treatment is termed treatment-resistant depression (TRD). There is no universally accepted definition for TRD. Several criteria have been suggested, including failure of at least, one adequate antidepressant Megestrol Acetate trial, two adequate antidepressant, trials, a trial with a monoamine oxidase inhibitor, lithium, or the newer heterocyclics, or at least one trial of electroconvulsive www.selleckchem.com/products/BMS-754807.html therapy (ECT).4 However, failure of at least, one adequate antidepressant trial appears to be emerging as the consensus operational criterion for TRD.5 Long-term studies indicate that 20% of patients with major depression remain unwell 2 years after the onset, of the illness.